Pulmonary arterial hypertension (PAH) frequently complicates systemic sclerosis (SSc), with an estimated prevalence of 6.4–9% [1, 2]. Although survival has improved with the advent of PAH-specific therapy, SSc-PAH continues to have poor prognosis, with a 3-year survival of 67% [3]. Current PAH management guidelines highlight the importance of risk stratification in guiding therapy [4].

中文翻译：

---

系统性硬化症相关肺动脉高压的风险评估：心脏指数与每搏输出量指数

肺动脉高压 (PAH) 经常并发系统性硬化症 (SSc)，估计患病率为 6.4–9% [1, 2]。尽管随着 PAH 特异性治疗的出现，生存率有所提高，但 SSc-PAH 的预后仍然很差，3 年生存率为 67% [3]。目前的 PAH 管理指南强调了风险分层在指导治疗中的重要性 [4]。